News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
AstraZeneca's Precision Lung Cancer Drug Approved in US; Daiichi Sankyo to Receive Milestone Payment USD45M
AstraZeneca (AZN.US) and its partner Daiichi Sankyo (4568.JP) have received approval from US regulators for their precision medicine Datroway, which is intended for previously trea...
Reset
Send
The window will close in 5 seconds
AstraZeneca's Precision Lung Cancer Drug Approved in US; Daiichi Sankyo to Receive Milestone Payment USD45M
Close
Recommend
2
Positive
0
Negative
1
 
SHORT SELL
 
STOCK INFO

AstraZeneca (AZN.US)      and its partner Daiichi Sankyo (4568.JP) have received approval from US regulators for their precision medicine Datroway, which is intended for previously treated patients with advanced non-small cell lung cancer. This marks the first time such a therapy has been approved in the US for lung cancer treatment.

AstraZeneca will make a milestone payment of USD45 million to Daiichi Sankyo.
(Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

Related NewsEIA Crude Oil Stocks Change for Jun/20 in United States is -5.836M, lower than the previous value of -11.473M. The forecast was -0.75M.

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.